Jasper Therapeutics

23 articles with Jasper Therapeutics

• Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

  8/12/2022

  Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on developing multiple new therapies for the field of stem and cellular medicine, today announced second quarter 2022 financial results and provided a corporate update.

• Jasper Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium

  6/23/2022

  Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company will participate at the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 28, 2022.

• Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock Conference

  6/7/2022

  Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company is participating in the William Blair 42nd Annual Growth Stock Conference, to be held in Chicago from June 6-9, 2022.

• Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022  

  6/6/2022

  Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that its 2022 Annual Meeting of Stockholders will be held on Thursday, June 23, 2022, at 10:00 a.m. Pacific Time.

• 

  Clinical Catch-Up: Amgen, AstraZeneca, Avillion Attack Asthma

  5/23/2022

  Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.

• Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia

  5/17/2022

  Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced the dosing of the first patient in the Company’s sponsored research of the Center for Definitive and Curative Medicine (CDCM) at the Stanford University School of Medicine for the study of JPS191 as a conditioning agent in the treatment of Fanconi Anemia.

• Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

  5/12/2022

  Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic stem cell therapies, announced first quarter 2022 financial results and provided a corporate update.

• Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting

  4/28/2022

  Jasper Therapeutics, Inc., (NASDAQ: JSPR) today announced that after discussion with the FDA the company plans to initiate a registrational study of JSP191 as a targeted, non-toxic conditioning agent in older patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) undergoing allogeneic hematopoietic (blood) cell transplantation.

• Jasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

  4/26/2022

  Jasper Therapeutics, Inc., (NASDAQ: JSPR) today announced updated efficacy, safety and pharmacokinetic data from its ongoing multicenter Phase 1 clinical trial of JSP191, the company’s first-in-class anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning regimen in older patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) undergoing allogeneic hematopoietic (blood) cell transplantation.

• Jasper Therapeutics to Host In-Person Key Opinion Leader Webinar on Transforming Hematopoietic Stem Cell Therapies

  4/22/2022

  Jasper Therapeutics, Inc. today announced that it will host an in-person key opinion leader (KOL) webinar on transforming the field of hematopoietic stem cell therapies on April 28, 2022, at 1:00 p.m. ET.

• Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting

  3/31/2022

  Jasper Therapeutics, Inc. (NASDAQ: JSPR) today announced that updated data from the Company’s ongoing study of JSP191 as single agent conditioning prior to allogeneic hematopoietic stem cell (HSC) re-transplant in patients with severe combined immunodeficiency (SCID) has been accepted for presentation as a late-breaking poster at the 2022 Clinical Immunology Society (CIS) Annual Meeting.

• Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Mar 25, 2022

  3/25/2022

  Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, announced that, on March 21, 2022, it granted an option to purchase 1,704,328 shares of Jasper’s voting common stock to Ronald Martell, Jasper’s newly appointed President and Chief Executive Officer.

• 

  BioSpace Movers & Shakers, March 25

  3/25/2022

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team

  3/21/2022

  Jasper Therapeutics, Inc. today announced changes to its management team, including the promotions of Jeet Mahal to the newly created position of Chief Operating Officer, and of Wendy Pang, M.D., Ph.D., to Senior Vice President of Research and Translational Medicine.

• Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update

  3/18/2022

  Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic stem cell therapies, today announced results for the fiscal year ended December 31, 2021, and provided a business update.

• Jasper Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference

  3/10/2022

  Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, announced that the Company is participating in the 32nd Annual Oppenheimer Healthcare investor conference, to be held virtually from March 15-17, 2022.

• Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive OfficerWilliam Lis to Continue as Chairman, Board of Directors

  2/28/2022

  Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, announced the appointment of Ronald Martell as the company’s Chief Executive Officer effective March 15, 2022.

• Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR

  2/24/2022

  Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic stem cell therapies, today announced that the preliminary data from a Phase 1b study of the Company’s JSP191 first-in-class anti-CD117 monoclonal antibody will be presented as a late breaking abstract at the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings (TCT).

• Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting

  12/8/2021

  Jasper Therapeutics, Inc. (NASDAQ: JSPR), today announced that data on JSP191 showing long-term benefits of hematopoietic stem cells (HSC) engraftment following targeted single-agent JSP191 conditioning in the treatment of severe combined immunodeficiency (SCID) will be presented at the 2021 American Society of Hematology (ASH) Annual Meeting.

• 

  Clinical Catch-Up: November 8-12

  11/15/2021

  It was another busy week for clinical trial news. Here’s a look.